• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mesoblast gains on A$29m investment deal with Mallinckrodt

December 23, 2016 By Sarah Faulkner

Mesoblast gains on A$29m investment deal with MallinckrodtShares in stem cell company Mesoblast Ltd (ASX:MSB) rose 7% to A$1.51 yesterday after it said that it entered into an equity purchase agreement with US drugmaker Mallinckrodt Pharmaceuticals (NYSE:MNK). Mallinckrodt will buy 20.04 million, or nearly 5%, of Mesoblast’s ordinary shares for A$1.48 apiece.

According to the agreement, Mallinckrodt will have 9 months to finalize commercial and development deals for 2 of Mesoblast’s product candidates – MPC-06-ID for the treatment of chronic low back pain and MSC-100-IV for the treatment of acute graft versus host disease. The commercial and development deals will be made in territories outside of Japan and China.

“We are pleased that Mallinckrodt has chosen to make an investment in Mesoblast,” Mesoblast CEO Silviu Itescu said in prepared remarks. “Mallinckrodt has a track record of success in commercializing medicines for immune-mediated diseases and pain management, and we believe that its major footprint in hospitals addressing acute care needs can be leveraged to realize the full commercial and clinical value of our innovative cellular medicines.”

“This agreement provides Mallinckrodt with a potential opportunity to extend our regenerative medicine pipeline in areas of high unmet patient need,” Mallinckrodt executive VP & chief scientific officer Dr. Steven Romano added. “We see Mesoblast as a leader in developing innovative cell-based medicines and look forward to establishing a fruitful partnership.”

MESO shares have lost 24% this year, taking hits after the company lost a series of US investors. In June this year, Mesoblast lost the support of Teva Pharmaceuticals, which had been backing the company’s phase III clinical trial. The trial is ongoing and is expected to continue until 2017.

After parting ways with Teva, the Australian company tapped into private funds with the help of some of Melbourne’s wealthy families. The group agreed to invest up to $120 million.

Filed Under: Featured, Funding Roundup, Stem Cells, Wall Street Beat Tagged With: Mallinckrodt Pharmaceuticals, Mesoblast Ltd.

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS